Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.69 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.69 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.61 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,S)-Ampa SCHEMBL68799 | 1.00 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL2458874 | 1.00 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL7200264 | 0.98 | GRIA1 (0.68) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL7200262 | 0.98 | GRIA1 (0.68) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL23242452 | 0.90 | GRIA1 (0.58) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL19086372 | 0.90 | GRIA1 (0.58) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (R,S)-Ampa SCHEMBL6553747 | 0.88 | GRIA1 (0.56) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| (S)-Ampa SCHEMBL28091565 | 0.85 | GRIA1 (0.53) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| SCHEMBL8812980 | 0.85 | GRIA1 (0.71) | GRIA1GRIA3GRIA2GRIA4MAPT | |
| SCHEMBL8812978 | 0.85 | GRIA1 (0.71) | GRIA1GRIA3GRIA2GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | claimed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | claimed |
| WO-2006077597-A2 | NOVEL NEUROPROTECTIVE COMPOUNDS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-07-27 | — | — | WO | claimed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | claimed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-12559750-B2 | Methods and compositions for treatment of polycystic kidney disease | Regulus Therapeutics Inc. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4694896-A1 | MODIFIED OLIGONUCLEOTIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE | Regulus Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4684014-A1 | METHODS FOR TREATING NERVOUS SYSTEM DISORDERS | Regulus Therapeutics Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250188466-A1 | Methods and Compositions for Treatment of Polycystic Kidney Disease | Regulus Therapeutics Inc. (US) | 2025-06-12 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250136979-A1 | Methods and Compositions for Avoiding Off-Target Effects | Regulus Therapeutics Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-113508195-B | Electrolyte for depositing dark grey/black rhodium/ruthenium alloy layers | 优美科电镀技术有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-0361687-B1 | Therapeutic polyamine-amides | BRITISH TECH GROUP (GB) | 1993-10-27 | — | — | EP | disclosed |
| US-5242918-A | Isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-09-07 | — | — | US | disclosed |
| US-5218000-A | Nervous system disorders, antiischemic agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-06-08 | — | — | US | disclosed |
| WO-1993005043-A1 | NOVEL ISATINOXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1993-03-18 | — | — | WO | disclosed |
| EP-0529636-A1 | Novel isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-03 | — | — | EP | disclosed |
| EP-0522494-A1 | Novel isatineoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-01-13 | — | — | EP | disclosed |
| EP-0361687-A1 | Therapeutic polyamine-amides | BTG INTERNATIONAL LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| WO-1990002114-A1 | THERAPEUTIC POLYAMINE-AMIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIA1 22/4885GRIA3 18/4885GRIA2 21/4885 |
| US-20250188466-A1 | Methods and Compositions for Treatment of Polycystic Kidney Disease | PKD1, PKD2, PCSK7 | GRIA1 3763/4885GRIA3 3011/4885GRIA2 3732/4885 |
| US-12559750-B2 | Methods and compositions for treatment of polycystic kidney disease | PKD1, PKD2, SLC26A4 | GRIA1 4329/4885GRIA3 4400/4885GRIA2 4567/4885 |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | GRIN1, GRIN2A, GRIN2B | GRIA1 21/4885GRIA3 20/4885GRIA2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.